SciNeuro Pharmaceuticals signs worldwide license and option agreement with GlaxoSmithKline.

M2 EQUITYBITES-June 2, 2022-SciNeuro Pharmaceuticals signs worldwide license and option agreement with GlaxoSmithKline

(C)2022 M2 COMMUNICATIONS http://www.m2.com

SciNeuro Pharmaceuticals, a US-based company involved in the discovery and development of innovative therapeutics for the treatment of CNS diseases, announced on Wednesday that it has signed a worldwide license and option agreement with UK-based GlaxoSmithKline (GSK).

The contract concentrates on inhibitors of Lp-PLA2, an enzyme that has been implicated in the pathogenesis of neurodegenerative diseases.

According to the contract, SciNeuro will receive a global license to intellectual property covering certain GSK Lp-PLA2 inhibitors and will be responsible for their further development via clinical proof-of-concept (PoC). Subsequent to the completion of the...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT